TipRanks (Wed, 2-Sep 7:30 AM ET)
Mid-cap healthcare stocks ranked by quant ratings after earnings season
Seeking Alpha News (Tue, 1-Sep 10:15 AM ET)
Globe Newswire (Wed, 19-Aug 8:56 AM ET)
Business Wire (Thu, 13-Aug 12:05 AM ET)
AbCellera’s Strong Phase 2 Data Spotlight New Highs and Next Steps for ABCL635
Market Chameleon (Wed, 12-Aug 3:07 AM ET)
These Have the Market Hot Zone Catalysts and Setups
Globe Newswire (Tue, 11-Aug 4:52 PM ET)
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Business Wire (Tue, 11-Aug 4:01 PM ET)
The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
Globe Newswire (Mon, 10-Aug 10:39 AM ET)
Market Chameleon (Mon, 10-Aug 6:31 AM ET)
AI Found an Influenza Target That Survives Viral Mutation
Globe Newswire (Mon, 10-Aug 9:10 AM ET)
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.
As of September 4, 2026, ABCL stock price declined to $11.43 with 1,841,794 million shares trading.
ABCL has a beta of 2.66, meaning it tends to be more sensitive to market movements. ABCL has a correlation of 0.10 to the broad based SPY ETF.
ABCL has a market cap of $3.70 billion. This is considered a Mid Cap stock.
Last quarter Abcellera Biologics - Common Shares reported $4 million in Revenue and -$.18 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.01.
In the last 3 years, ABCL traded as high as $12.58 and as low as $1.89.
The top ETF exchange traded funds that ABCL belongs to (by Net Assets): CPAI, SPDW, GWX, ONEQ, AVUS.
ABCL has outperformed the market in the last year with a return of +186.5%, while the SPY ETF gained +20.8%. In the last 3 month period, ABCL beat the market returning +99.8%, while SPY returned +2.4%. However, in the most recent 2 weeks ABCL has underperformed the stock market by returning -1.2%, while SPY returned +1.0%.
ABCL support price is $10.86 and resistance is $12.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL shares will trade within this expected range on the day.